Adial Pharmaceuticals granted 180-day Nasdaq extension to meet $1.00 bid price rule by March 2, 2026

ADIAL PHARMACEUTICALS, INC.

Received Nasdaq extension until March 2, 2026 to regain compliance with minimum $1.00 bid price requirement.
Initial 180-day compliance period ended September 1, 2025; extension granted due to meeting other listing criteria.
Company must maintain closing bid ≥ $1.00 for 10 consecutive business days before deadline.
If necessary, company will consider a reverse stock split to cure deficiency.
No immediate effect on trading; stock continues on Nasdaq Capital Market under symbol ADIL.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.